Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany

NCT ID: NCT01174420

Last Updated: 2011-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this prospective randomized study is to investigate the efficacy and safety of trabeculectomy with ologen Collagen Matrix versus trabeculectomy using mitomycin C (MMC) in patients with medically uncontrolled open angle glaucoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ologen® Collagen Matrix (CM) is an artificial extracellular matrix (ECM) specifically configured to support repair in connective and epithelial ocular tissue. The device is constructed so as to minimize random growth of fibroblasts and instead to allow them to grow through the pores in the matrix. ologen® CM is a biodegradable scaffold matrix, inducing a regenerative non-scarring wound healing process without using anti-fibrotic agents. For application in glaucoma filtration surgery, ologen® CM is designed to prevent scar formation (subconjunctival and scleral flap scarring is the major risk factor for failure of trabeculectomy). After implanting the ologen® CM on top of the scleral flap in the subconjunctival space, a functional bleb can be created.

The aim of the present study is to determine the effectiveness of the ologen® CM and reduce wound scarring, thereby increasing success of trabeculectomy without side effects of MMC. A means of producing better success rate and reduced complications is the purpose of ologen® Collagen Matrix for the aid of glaucoma surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ologen Collagen Matrix

Group Type EXPERIMENTAL

Use of ologen Collagen Matrix in trabeculectomy

Intervention Type DEVICE

After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing

Mitomycin-C (MMC)

Group Type ACTIVE_COMPARATOR

Use of Mitomycin-C in trabeculectomy

Intervention Type DRUG

After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Use of ologen Collagen Matrix in trabeculectomy

After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing

Intervention Type DEVICE

Use of Mitomycin-C in trabeculectomy

After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or over
* Uncontrolled open-angle glaucoma
* Subject is willing to sign informed consent
* Subject is able and willing to complete post-operative follow-up requirements

Exclusion Criteria

* Inflammatory eye diseases
* Angle-closure glaucoma
* Secondary glaucoma with anatomical malformations of the eye
* Subjects having single functional eye
* Previous conjunctival surgery
* Known allergic reactions to ingredients of ologen Collagen Matrix
* Excessive myopia (axial length (AL)\> 27 mm or more than -10 diopters)
* Previous vitrectomy eye surgery
* Subjects do not consent to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aeon Astron Europe B.V.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Ophthalmology, University of Cologne, Germany

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Dietlein, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Ophthalmology, University of Cologne, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University Hospital of Cologne

Cologne, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas Dietlein, MD

Role: CONTACT

+49-221-478-5862 ext. 4300

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Dietlein, MD

Role: primary

+49-221-478-5862 ext. 4300

References

Explore related publications, articles, or registry entries linked to this study.

Park J, Rittiphairoj T, Wang X, E JY, Bicket AK. Device-modified trabeculectomy for glaucoma. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD010472. doi: 10.1002/14651858.CD010472.pub3.

Reference Type DERIVED
PMID: 36912740 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AAE-CT-DEU-2009-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.